A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate Safety And Efficacy Of PF-04965842 In Subjects With Moderate To Severe Psoriasis
Phase of Trial: Phase II
Latest Information Update: 26 Sep 2017
At a glance
- Drugs PF 4965842 (Primary)
- Indications Plaque psoriasis
- Focus Proof of concept; Therapeutic Use
- Sponsors Pfizer
- 26 Sep 2017 Results published in the British Journal of Dermatology.
- 10 Jun 2017 Biomarkers information updated
- 17 Dec 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.